房颤患者创伤后恢复口服抗凝与卒中及出血风险:全国性队列研究
丹麦全国注册研究纳入4541例口服抗凝治疗的房颤创伤患者,90天内60.6%恢复VKA、16.7%恢复NOAC、22.7%未恢复。与未恢复相比,恢复VKA或NOAC与全因死亡和缺血性卒中风险降低相关,大出血风险增加,但复发性创伤风险无显著增加。
要点
- 房颤患者创伤后恢复VKA或NOAC与全因死亡和缺血性卒中风险降低相关。
- 恢复VKA或NOAC与大出血风险增加相关,但复发性创伤风险无显著增加。
- 创伤后停用口服抗凝可能并不合理。
核心结论
- 房颤患者创伤后恢复VKA或NOAC与全因死亡和缺血性卒中风险降低相关,大出血风险增加,但复发性创伤风险无额外增加。
- 创伤后停用口服抗凝可能并不合理。
研究设计与样本
- 丹麦全国注册研究(2005-16年),纳入4541例口服抗凝治疗的房颤创伤患者。
- 创伤定义为创伤性脑损伤、髋部骨折或创伤性躯干/腹部损伤。
- 随访自出院后90天开始,采用时变多因素Cox回归分析比较。
主要发现
- 出院后90天内60.6%恢复VKA(中位年龄80,CHA2DS2-VASc=4,HAS-BLED=2),16.7%恢复NOAC(中位年龄81,CHA2DS2-VASc=4,HAS-BLED=2),22.7%未恢复(中位年龄81,CHA2DS2-VASc=4,HAS-BLED=3)。
- 9.5%的患者从VKA转换为NOAC。
- 2009年以来口服抗凝恢复趋势增加(P<0.0001),尤其是NOAC(P<0.0001)。
- 与未恢复相比,恢复VKA和NOAC的全因死亡HR分别为0.48(95%CI 0.42-0.53)和0.55(95%CI 0.47-0.66)。
- 与未恢复相比,恢复VKA和NOAC的缺血性卒中HR分别为0.56(95%CI 0.43-0.72)和0.54(95%CI 0.35-0.82)。
临床怎么用
- 房颤患者发生创伤后,不应常规停用口服抗凝,应考虑恢复VKA或NOAC治疗。
- 恢复抗凝时需权衡缺血性卒中与出血风险,但复发性创伤风险未见额外增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We examined the risks of all-cause mortality, stroke, major bleeding, and recurrent traumatic injury associated with resumption of vitamin K antagonists (VKAs) and non-VKAs oral anticoagulants (NOACs) following traumatic injury in atrial fibrillation (AF) patients. METHODS AND RESULTS: This was a Danish nationwide registry-based study (2005-16), including 4541 oral anticoagulant (OAC)-treated AF patients experiencing traumatic injury (defined as traumatic brain injury, hip fracture, or traumatic torso or abdominal injury). Within 90 days following discharge from traumatic injury, 60.6% resumed VKA (median age = 80, CHA2DS2-VASc = 4, HAS-BLED = 2), 16.7% resumed NOAC (median age = 81, CHA2DS2-VASc = 4, HAS-BLED = 2), and 22.7% did not resume OAC treatment (median age = 81, CHA2DS2-VASc = 4, HAS-BLED = 3). Switch from VKA to NOAC occurred among 9.5%. Since 2009, the trend in OAC resumption increased (P-value <0.0001), in particular with NOACs (P-value <0.0001). Follow-up started 90 days after discharge, and time-varying multiple Cox regression analyses were used for comparisons. Compared with non-resumption, VKA and NOAC resumption were associated with lower hazard [95% confidence interval (CI)] of all-cause mortality [hazard ratio (HR) 0.48 (0.42-0.53) and HR 0.55 (0.47-0.66), respectively] and ischaemic stroke [HR 0.56 (0.43-0.72) and HR 0.54 (0.35-0.82), respectively], increased major bleeding hazard [HR 1.30 (1.03-1.64) and HR 1.15 (0.81-1.63), respectively], and similar hazard of recurrent traumatic injury [HR 0.93 (0.73-1.18) and HR 0.87 (0.60-1.27), respectively]. CONCLUSION: AF patients resuming VKA and NOAC treatment following traumatic injury have lower hazard of all-cause mortality and ischaemic stroke, increased hazard of major bleeding but without additional hazards of recurrent traumatic injury. Withholding OAC following a traumatic injury in AF patients may not be warranted.
引用
- Staerk L, Fosbøl EL, Lamberts M, et al. Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2018. PMID: 29165556. doi:10.1093/eurheartj/ehx598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。